title: Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
abstract: BACKGROUND
  Leucine-rich and immunoglobulin-like domains 1-3 (LRIG1-3) proteins have been implicated in the regulation of EGFR signalling. In the present study, we investigated the clinical implications of the expression of EGFR and LRIG1-3 in oesophageal carcinoma, as well as the correlation between their expression levels and the chemosensitivity of oesophageal carcinoma cell lines.
  
  
  METHODS
  Tumours from 80 patients with oesophageal carcinoma were investigated for the expression of EGFR and LRIG proteins by immunohistochemistry. Oesophageal carcinoma cell lines were investigated for their expression of EGFR and LRIG1, 2, and 3 by quantitative real time RT-PCR and for their sensitivity to commonly used chemotherapeutics by a cytotoxicity assay.
  
  
  CONCLUSIONS
  Based on a total score of intensity and expression rates, a trend towards survival difference was found for EGFR (p = 0.09) and LRIG2 (p = 0.18) whereas for LRIG1 and -3 there was no trend towards any association with survival. Correlation analysis revealed a correlation with the clinical expression of EGFR and LRIG3 (p = 0.0007). Significant correlations were found between LRIG1 expression levels and sensitivity to cisplatin (r = -0.74), docetaxel (r = -0.69), and vinorelbine (r = -0.82) in oesophageal carcinoma cell lines. EGFR and the LRIG proteins may be functionally involved in oesophageal carcinoma, but larger materials are needed to fully elucidate the clinical implication.
authors.affiliation: Section of Oncology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden.
authors.forename: Xuping
authors.initials: X
authors.lastname: Wu
authors.forename: Håkan
authors.initials: H
authors.lastname: Hedman
authors.forename: Michael
authors.initials: M
authors.lastname: Bergqvist
authors.forename: Stefan
authors.initials: S
authors.lastname: Bergström
authors.forename: Roger
authors.initials: R
authors.lastname: Henriksson
authors.forename: Joachim
authors.initials: J
authors.lastname: Gullbo
authors.forename: Johan
authors.initials: J
authors.lastname: Lennartsson
authors.forename: Patrik
authors.initials: P
authors.lastname: Hesselius
authors.forename: Simon
authors.initials: S
authors.lastname: Ekman
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use; D000077143:Docetaxel; D066246:ErbB Receptors / Q000378:metabolism*; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008565:Membrane Proteins / Q000378:metabolism*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D011379:Prognosis; D015996:Survival Rate; D013548:Sweden / Q000453:epidemiology; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; C484445:LRIG1 protein, human; C488673:LRIG2 protein, human; C496406:LRIG3 protein, human; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D043823:Taxoids; D000077143:Docetaxel; D014747:Vinblastine; D066246:ErbB Receptors; D002945:Cisplatin; D000077235:Vinorelbine